NASDAQ:ROIV

Roivant Sciences Stock News

Healthcare > Biotechnology

Buy ROIV

*Your capital is at risk

$31.25

-0.180 (-0.573%)

At Close: Jun 22, 2026

Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease

10:00am, Wednesday, 17'th Sep 2025

Shares of Roivant Sciences extended their breakout Wednesday, stoked by promising test results in a difficult-to-treat autoimmune disease.

Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial

08:21am, Wednesday, 17'th Sep 2025

Roivant and partner Priovant Therapeutics said on Wednesday that their experimental drug for a rare disease affecting both skin and muscle health has shown promising results in a late-stage clinical t

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

07:00am, Wednesday, 17'th Sep 2025

BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VAL

Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

04:30pm, Thursday, 11'th Sep 2025

BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in B

Roivant Sciences Ltd. (ROIV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

08:25pm, Monday, 08'th Sep 2025

Roivant Sciences Ltd. (NASDAQ:ROIV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 5:35 PM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participa

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

07:00am, Thursday, 04'th Sep 2025

Orphan drug designation from Japan's Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeti

Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript

11:07pm, Wednesday, 03'rd Sep 2025

Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-of-Concept Study Remission Data Transcript Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

01:01pm, Wednesday, 03'rd Sep 2025

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared a

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by